SciSparc-Clearmind File International Patent for New Eating Disorder Treatment

SciSparc Ltd., a specialized clinical-stage pharmaceutical enterprise, has announced a significant advancement in its collaboration with Clearmind Medicine Inc. This partnership has resulted in the filing of an international patent application for a novel treatment aimed at addressing anorexia, bulimia, and other eating disorders. The patent centers on the innovative use of 3-Methylmethcathinone (3-MMC) in combination with SciSparc’s Palmitoylethanolamide (PEA), an approach designed to tackle the complex neurobiological and psychological factors underlying these conditions. This development represents a promising new direction in the treatment of eating disorders.

Eating disorders are recognized as severe mental health issues that significantly affect individuals' physical health, emotional well-being, and daily functioning. They are particularly prevalent among young women, ranking among the top ten causes of disability, and they carry one of the highest mortality rates among mental health disorders. Recent research indicates that as many as 70 million individuals worldwide are affected by eating disorders, with an alarming rise in prevalence among children and adolescents. The global prevalence of eating disorders increased from 3.4% to 7.8% between 2000 and 2018, highlighting the urgent need for innovative therapeutic strategies.

SciSparc Ltd., listed on the Nasdaq under the symbol SPRC, is led by a team of seasoned executives and scientists dedicated to developing and refining a portfolio of cannabinoid-based pharmaceuticals. The company's current drug development projects focus on THC and non-psychoactive CBD formulations. These include SCI-110, which is being developed for the treatment of Tourette Syndrome as well as Alzheimer's disease and associated agitation, and SCI-210, aimed at addressing autism spectrum disorder and status epilepticus. In addition to its pharmaceutical pursuits, SciSparc has a controlling interest in a subsidiary that specializes in the sale of hemp seed oil products on Amazon Marketplace.

Clearmind Medicine Inc., a clinical-stage psychedelic pharmaceutical biotech company, is focused on discovering and developing novel psychedelic-derived therapeutics to address widespread and underserved health issues, such as alcohol use disorder. Clearmind’s primary mission is to research and develop these compounds with the aim of commercializing them as regulated medicines, foods, or supplements. The company is strategically building its intellectual property portfolio, which currently includes nineteen patent families with 31 granted patents. Clearmind, traded on Nasdaq under the symbol CMND and the Frankfurt Stock Exchange under CWY0, continuously seeks to expand its patent holdings to strengthen its position in the emerging field of psychedelic medicine.

The collaboration between SciSparc and Clearmind represents a significant step forward in the quest to develop more effective treatments for eating disorders. By combining their expertise in cannabinoid and psychedelic-derived therapeutics, the two companies are poised to make a meaningful impact on the lives of individuals suffering from these debilitating conditions. This innovative approach not only underscores the potential of their combined therapies but also highlights the growing interest in exploring alternative treatment avenues for complex neuropsychiatric disorders.